Skip to main content
SpringerLink
Log in

A Guide to the Treatment of Lower Respiratory Tract Infections

  • Practical Therapeutics
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Acute bronchitis is usually a viral infection which, unless there is a special disposition, does not require antibiotic therapy. For the initial oral chemotherapy of bacterial infections of the lower respiratory tract (chronic bronchitis, pneumonia) the effective and well tolerated cephalosporins, macrolides and amoxicillin plus β-lactamase-inhibitor are recommended. In complicated cases with severe underlying disease, longer history or frequent exacerbations, quinolones should be given if Gramnegative infections are suspected or if initial therapy with other substances has failed. If Legionella, Mycoplasma or Chlamydia spp., so-called ‘atypical’ pathogens, are involved, macrolide antibiotics are the therapy of first choice. Special attention should be given to the increase in resistance against cotrimoxazole (trimethoprim-sulfamethoxazole) and tetracyclines. In hospitals where primary pneumonias are treated preferentially by intravenous medication, therapy should be switched to oral antibiotics as soon as feasible (follow-up therapy).

For severely ill patients with secondary pneumonia and underlying disease, second generation cephalosporins with aminoglycosides, or monotherapy with third generation cephalosporins are recommended. In very severe, high-risk cases, third generation cephalosporins, combinations with high-dosage quinolones or ureidopenicillins plus β-lactamase—inhibitors are suitable. Future development in the antibiotic treatment of respiratory infections will follow the current trend of lower dosages, with the clear objective of shortening treatment periods and achieving earlier discharge from hospital.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pennington J. Hospital acquired pneumonia. In: Respiratory infections: diagnosis and management. 2nd ed. New York: Raven Press, 1988

    Google Scholar 

  2. Bodey GP. Empirical antibiotic therapy for fever in neutropenic patients. Clm Infect Dis 1993; 17 Suppl. 2: 378–84

    Article  Google Scholar 

  3. Atherton SF, White DJ. Stomach as source of bacteria colonising respiratory tract during artificial ventilation. Lancet 1978; 2: 968

    Article  PubMed  CAS  Google Scholar 

  4. Finegold SM. Aspiration pneumonia. Rev Infect Dis 1991; 13 Suppl. 9: 737–42

    Article  CAS  Google Scholar 

  5. Focht J, Klietmann W, Nösner K, et al. In-vitro-Aktivität von Cefuroxim im Vergleich mit anderen oralen Antibiotika. Munch Med Wochenschr 1990; 132: 226–9

    Google Scholar 

  6. MacFarlane JT, Colville A, Guion A, et al. Prospective study of aetiology and outcome of adult lower-respiratory-tract infections. Lancet 1993; 341: 511–4

    Article  PubMed  CAS  Google Scholar 

  7. Garibaldi RA. Epidemiology of community-acquired respiratory tract infections in adults. Am J Med 1985; 78: 32–7

    Article  PubMed  CAS  Google Scholar 

  8. Weinke Th, Trautmann M, Söffker K, et al. Die Pneumonie bei Erwachsenen. Munch Med Wochenschr 1988; 130: 641–3

    Google Scholar 

  9. Mandell LA, Marrie TJ, Niederman MS et al. Initial antimicrobial treatment of hospital acquired pneumonia in adults: a conference report. Can J Infect Dis 1993; 4: 317–20

    PubMed  CAS  Google Scholar 

  10. Ferlinz R, Meyer-Davila A. Epidemiologie ambulant erworbener und nosokomialer Pneumonien. Atemwegs Lungenkrankh 1988; 14: 6–14

    Google Scholar 

  11. Kappstein I, Daschner F. Nosokomiale Pneumonien auf Intensivpflegestationen. Intensivmed 1988; 25: 95–7

    Google Scholar 

  12. Kemmerich B, Rahlwes M, Vogel-Hartmann H, et al. Ambulant erworbene Pneumonien. Dtsch Med Wochenschr 1989; 114: 1471–7

    Article  PubMed  CAS  Google Scholar 

  13. MacFarlane JT, Finch RG, Ward MJ, et al. Hospital study of adult community-acquired pneumonia. Lancet 1982; 2: 255

    Article  PubMed  CAS  Google Scholar 

  14. Martin RE, Bates JH. Atypical pneumonia. Infect Dis Clin North Am 1991; 5: 585–601

    PubMed  CAS  Google Scholar 

  15. Kayser FH. Pneumonien in der Praxis. Schweiz Rundsch Med Prax 1987; 76: 175–9

    PubMed  CAS  Google Scholar 

  16. Adam D, Goertz G, Helwig H, et al. Rationaler Einsatz oraler Antibiotika in der Praxis; Empfehlungen einer Expertenkommission der Paul-Ehrlich Gesellschaft für Chemotheraphie e.V. Munch Med Wochenschr 1993; 135: 591–9

    Google Scholar 

  17. Simmen HP, Siegenthaler W, Lüthy R. Erythromycin. Dtsch Med Wochenschr 1982; 107: 1480

    Article  PubMed  CAS  Google Scholar 

  18. O’Neil SJ, Miller ED, Coles SJ, et al. Safety and efficacy of clarithromycin in the treatment of acute mild to moderate respiratory tract infections. Ir Med J 1991; 84: 33–5

    Google Scholar 

  19. Peters DH, Friedel AA, McTavish D. Azithromycin: a review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs 1992; 44: 750–99

    Article  PubMed  CAS  Google Scholar 

  20. Nicotra MB, Rivera M, Awe RJ. Antibiotic therapy of acute exacerbation of chronic bronchitis. Ann Intern Med 1982; 97: 18

    PubMed  CAS  Google Scholar 

  21. Bauernfeind A, Jungwirth R, Schweighart S et al. Anti-bakterielle Aktivität und beta-Laktamase-Stabilität von elf Oralcephalosporinen. Infection 1990; 18 Suppl. 3: 155–67

    Article  Google Scholar 

  22. Moellering RC, Waldvogel FA, editors. Cefaclor: a decade of experience. Clin Ther 1988; 11 Suppl. A: 1-94

  23. Bingen E, Lambert-Zechovsky N, Doit C et al. Killing kinetics of cefuroxime axetil against Haemophilus influenzae in an in-vitro model simulating serum concentration profiles after oral administration. J Antimicrob Chemother 1991; 28: 533–6

    Article  PubMed  CAS  Google Scholar 

  24. Brogden RN, Campoli-Richards DM. Cefixime: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 1989; 38: 524–50

    Article  PubMed  CAS  Google Scholar 

  25. Neu HC, McCracken GH, editors. Clinical pharmacology and efficacy of cefixime. Proceedings of a conference. Pediatr Infect Dis J 1987; 6: 949–1009

  26. Marget W, Benner U, editors. Cefixime. Infection 1990; 18 Suppl. 3: S115-68

  27. Cefpodoxime proxetil: a third-generation oral cephalosporin [editorial]. J Antimicrob Chemother 1990; 26 Suppl. 1: 1-101

    Google Scholar 

  28. Nolen TM, Phillips HL, Hutchinson J, et al. Comparison of cefuroxime axetil and cefaclor for patients with lower respiratory tract infections presenting at a rural family practice clinic. Curr Ther Res 1988; 44: 821–9

    Google Scholar 

  29. Schleupner CJ, Anthony WC, Tan J, et al. Blinded comparison of cefuroxime to cefaclor for lower respiratory tract infections. Arch Intern Med 1988; 148: 343–8

    Article  PubMed  CAS  Google Scholar 

  30. Brambilla C, Kastanakis S. Cefuroxime versus Augmentin follow-on therapies in the treatment of lower respiratory tract infections. In: Adam D, Lode H, Rubinstein E, editors. Recent advances in chemotherapy. Proceedings of the 17th Internat Congress on Chemotherapy; 1991 Jun 23–28: Berlin. München: Futuramed Verlag, 1992: 1640–1

    Google Scholar 

  31. Hebblethwaite FM, Brown GW, Cox DM. A comparison of the efficacy and safety of cefuroxime axetil and Augmentin in the treatment of upper respiratory tract infections. Drugs Exp Clin Res 1987; 13: 91–4

    PubMed  CAS  Google Scholar 

  32. Spencer RC. A comparison of the efficacy and safety of cefuroxime axetil and amoxycillin in the treatment of lower respiratory tract infections. 6th Mediterranen Congress of Chemotherapy; 1988 May 22–27, Taormina-Giardini, Naxos

    Google Scholar 

  33. Vogel F, Maas AB. Clinical and bacteriological experience with cefuroxime axetil in the treatment of lower respiratory tract infections [abstract]. Z Antimikrob Antineoplast Chemother 1989; 7 Suppl. 1: 50

    Google Scholar 

  34. Kohl FV, Köhler CO. A multicenter clinical trial to compare two antibiotic regimes: cefuroxime i.v. followed by cefuroxime axetil orally (group 1) versus cefotiam i.v. (group 2). In: Adam D, Lode H, Rubinstein E, editors. Recent Advances in Chemotherapy. Proceedings of the 17th Internat Congr Chemother; 1991 June 23–28: Berlin. München: Futuramed Verlag, 1992: 2068–9

    Google Scholar 

  35. Meyers BR. Management of community acquired lower respiratory tract infections with cefuroxime axetil: clinical overview. In: Emmerson AM, editor. The management of lower respiratory tract infections with cefuroxime axetil. Royal Society of Medicine Services International Congress and Symposium Series No. 124; 29 May 1987. London: Royal Society of Medicine Servia, 1987

    Google Scholar 

  36. Vogel F. Orale Cephalosporine bei unteren Atemwegsinfektionen. FAC 1993; 12–1: 135–47

    Google Scholar 

  37. Kiani R, Johnson D, Nelson B. Comparative multicenter studies of cefixime and amoxicillin in the treatment of respiratory tract infections. Am J Med 1988; 85: 6–13

    Article  PubMed  CAS  Google Scholar 

  38. Dorow P. Safety and efficacy of cefixime versus cefaclor in respiratory tract infections. J Chemother 1989; 1: 257–60

    PubMed  CAS  Google Scholar 

  39. Zuck P, Rio Y, Ichou F. Efficacy and tolerance of cefpodoxime proxetil compared with ceftriaxone in vulnerable patients with bronchopneumonia. J Antimicrob Chemother 1990; 26 Suppl. E: 71

    Article  PubMed  Google Scholar 

  40. Periti P, Novelli A, Schildwachter G. Efficacy and tolerance of cefpodoxime proxetil compared with co-amoxiclav in the treatment of exacerbations of chronic bronchitis. J Antimicrob Chemother 1990; 26 Suppl. E: 63–9

    Article  PubMed  Google Scholar 

  41. Vogel F. Efficacy and tolerability of clarithromycin in the short-course treatment of acute respiratory infections. Drug Invest 1991; 3: 205–9

    Article  Google Scholar 

  42. Heinrich R, Mitschka J. Multicenter, randomized comparative study of ceftazidime vs. cefotaxime in the treatment of patients 65 years of age and older with nosocomial bacterial pulmonary and urinary tract infections. Int J Exp Clin Chemother 1991; 4: 40–7

    Google Scholar 

  43. Niedermann MS, Bass JB, Campbell GD et al. Guidelines for the initial management of adults with community-acquired pneumonia. Am Rev Resp Dis 1993; 148: 1418–26

    Google Scholar 

  44. Yangco BG, Baird I, Lorber B, et al. Comparative efficacy and safety of ceftizoxime, cefotaxime and latamoxef in the treatment of bacterial pneumonia in high risk patients. J Antimicrob Chemother 1987; 19: 239–48

    Article  PubMed  CAS  Google Scholar 

  45. Norrby S, Finch R, Glomser M et al. Monotherapy in serious hospital-acquired infections; a clinical trial of ceftazidime versus imipenem/cilastatin. J Antimicrob Chemother 1993; 31: 927–37

    Article  PubMed  CAS  Google Scholar 

  46. Rubinstein E, Lode H, Grassi C et al. Ceftazidime monotherapy vs. ceftriaxone/tobramycin for serious hospital-acquired Gram-negative infections. Clin Infect Dis. In press

  47. De Pauw BE, Stanley C, Deresinski MD. ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. Ann Intern Med 1994; 120: 834–44

    PubMed  Google Scholar 

  48. Freifeld AG, Walsh T, Marshall D et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995; 13: 165–76

    PubMed  CAS  Google Scholar 

  49. Konsensuskonferenz der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. Cephalosporine zur parenteralen Anwendung. Chemotherapie J 1994; 3: 101–15

    Google Scholar 

  50. James NC, Donn KH, Collins JJ et al. Pharmacokinetics of cefuroxime axetil and cefaclor: relationship of concentrations in serum to MICs for common respiratory pathogens. Antimicrob Agents Chemother 1991; 9: 1860–3

    Article  Google Scholar 

  51. Tremblay D, Dupront A, Ho C, et al. Pharmacokinetics of cefpodoxime in young and elderly volunteers after single doses. J Antimicrob Chemother 1990; 26 Suppl. E: 21–3

    Article  PubMed  CAS  Google Scholar 

  52. Neu HC. The development of macrolides: clarithromycin in perspective. J Antimicrob Chemother 1991; 27 Suppl. A: 1–9

    Article  PubMed  CAS  Google Scholar 

  53. Lamp KC, O’Baily EM, Rybak MJ. Ofloxacin clinical pharmacokinetics. Clin Pharmacokinet 1992; 22: 32–46

    Article  PubMed  CAS  Google Scholar 

  54. Bolaeret JM, Valcke Y, Schurgers M, et al. The pharmacokinetics of ciprofloxacin in patients with impaired renal function. J Antimicrob Chemother 1985; 16: 87–98

    Article  Google Scholar 

  55. Gasser TC, Ebert SC, Graversen PH, et al. Pharmacokinetic study of ciprofloxacin in patients with impaired renal function. Am J Med 1987; 82 Suppl. 4A: 139–41

    Google Scholar 

  56. Wingender W, Beermann D, Förster D, et al. Mechanism of renal excretion of ciprofloxacin (BAY 09867), a new quinolone carbocylic acid derivative in humans. Chemioterapia 1985; 4 Suppl. 2: 403–4

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Krankenhaus Hofheim, Lindenstrasse 10, D-65719, Hofheim im Taunus, Germany

    Friedrich Vogel

Authors
  1. Friedrich Vogel
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vogel, F. A Guide to the Treatment of Lower Respiratory Tract Infections. Drugs 50, 62–72 (1995). https://doi.org/10.2165/00003495-199550010-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199550010-00006

Keywords

Search

Navigation